• Global Wellness Strategies (LOAN) and KaleidoMyco are introducing a one-shot drink that combines functional mushrooms with hemp extract
  • KaleidoMyco will launch a blend of functional mushrooms in three flavours including lemon-lime, orange citrus, and grape
  • The one-shot utilizes proprietary extraction technologies
  • KaleidoMyco is one of the world’s first companies combining hemp extract, adaptogens, and myco-based ingredients
  • Global Wellness Strategies is down 17.74 per cent on the day, with shares of the company trading at C$0.26 at 9:30 am ET

Global Wellness Strategies (LOAN) and KaleidoMyco are introducing a one-shot drink that combines functional mushrooms with hemp extract.

KaleidoMyco will launch a blend of functional mushrooms in three likeable flavours including lemon lime, orange citrus, and grape. The one-shot utilizes proprietary extraction technologies.

The company says various anti-inflammatory compounds and substances in functional mushrooms offer relief from arthritis, muscle strain, and other common inflammatory conditions.

“The team at KaleidoMyco are innovators, mycologists and formulists, who look to introduce new wellness products that help consumers take care of themselves first. It is a boost to our minds and bodies not a cure is their philosophy and a theory that resonates during COVID 19. Bringing revenues to the bottom line in short order continues to be their fiscal mandate. We anticipate an online storefront and digital rollout on platforms such as Amazon shortly. A direct sales network plus distributors should be in full-swing by end of the next quarter,” said Global Wellness Strategies CEO Meris Kott.

KaleidoMyco is one of the world’s first companies combining hemp extract, adaptogens, and myco-based ingredients to produce world-class, data-driven, science-based wellness products.

Global Wellness Strategies is a prospect generator that provides high-growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products.

The focus of the company is on global wellness, hemp and CBD, healthcare-related target companies.

Global Wellness Strategies is down 17.74 per cent on the day, with shares of the company trading at C$0.26 at 9:30 am ET.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.